Document is current
Any future updates will be listed below
-
Authors
Zom, Gijs G.
Willems, Marian M. J. H. P.
Khan, Selina
van der Sluis, Tetje C.
Kleinovink, Jan Willem
Camps, Marcel G. M.
van der Marel, Gijsbert A.
Filippov, Dmitri V.
Melief, Cornelis J. M.
Ossendorp, Ferry
-
Funding
Funding for this research was provided by:
KWF Kankerbestrijding (UL2007-3906)
- License Information
-
More Information
Article History
Received: 23 February 2018
Accepted: 16 November 2018
First Online: 12 December 2018
Ethics approval and consent to participate
: Not applicable to this study.
: Not applicable to this study.
: CJM Melief is chief scientific officer of biotech company ISA (Immune System Activation), aiming at development of synthetic peptide –based cancer vaccines, including conjugates between a proprietary TLR ligand and synthetic long peptides. As CSO, CJM Melief receives a salary from ISA and is in possession of stock appreciation rights. In addition, CJM Melief is inventor on numerous patents that are licensed to or owned by ISA dealing with synthetic long peptide vaccines or dealing with the proprietary TLR ligand used in this paper.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
